Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
AEG35156-204: A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
Status: Archived
New York Medical College
491
mi
from 43215
Valhalla, NY
A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
AEG35156-204: A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
Status: Archived
Updated: 1/1/1970
New York Medical College
491
mi
from 43215
Valhalla, NY
A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
AEG35156-204: A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
Status: Archived
Taussig Cancer Center, Cleveland Clinic Foundation
138
mi
from 43215
Cleveland, OH
A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
AEG35156-204: A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
Status: Archived
Updated: 1/1/1970
Taussig Cancer Center, Cleveland Clinic Foundation
138
mi
from 43215
Cleveland, OH
A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
AEG35156-204: A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
Status: Archived
Scott and White Hosptial, Texas A&M University
1018
mi
from 43215
Temple, TX
A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
AEG35156-204: A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
Status: Archived
Updated: 1/1/1970
Scott and White Hosptial, Texas A&M University
1018
mi
from 43215
Temple, TX
Hydroxychloroquine in Untreated B-CLL Patients
Phase II Study to Evaluate the Tolerability and Efficacy of Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients With Hydroxychloroquine.
Status: Archived
Long Island Jewish Medical Center
494
mi
from 43215
New Hyde Park, NY
Hydroxychloroquine in Untreated B-CLL Patients
Phase II Study to Evaluate the Tolerability and Efficacy of Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients With Hydroxychloroquine.
Status: Archived
Updated: 1/1/1970
Long Island Jewish Medical Center
494
mi
from 43215
New Hyde Park, NY
High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML
High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for Therapy-Related Myelodysplastic Syndrome/Therapy -Related Acute Myeloid Leukemia
Status: Archived
University of Chicago
270
mi
from 43215
Chicago, IL
High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML
High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for Therapy-Related Myelodysplastic Syndrome/Therapy -Related Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
University of Chicago
270
mi
from 43215
Chicago, IL
Infusional C-myb ASODN in Advanced Hematologic Malignancies
Infusional C-myb Antisense Oligodeoxynucleotide in Advanced Hematological Malignancies
Status: Archived
Abamson Cancer Center of the University of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Infusional C-myb ASODN in Advanced Hematologic Malignancies
Infusional C-myb Antisense Oligodeoxynucleotide in Advanced Hematological Malignancies
Status: Archived
Updated: 1/1/1970
Abamson Cancer Center of the University of Pennsylvania
414
mi
from 43215
Philadelphia, PA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
City of Hope Comprehensive Cancer Center
1955
mi
from 43215
Duarte, CA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Updated: 1/1/1970
City of Hope Comprehensive Cancer Center
1955
mi
from 43215
Duarte, CA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
640
mi
from 43215
Boston, MA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Updated: 1/1/1970
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
640
mi
from 43215
Boston, MA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Cincinnati Children's Hospital Medical Center
97
mi
from 43215
Cincinnati, OH
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Updated: 1/1/1970
Cincinnati Children's Hospital Medical Center
97
mi
from 43215
Cincinnati, OH
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Children's Hospital at Downstate
481
mi
from 43215
Brooklyn, NY
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Updated: 1/1/1970
Children's Hospital at Downstate
481
mi
from 43215
Brooklyn, NY
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Fred Hutchinson Cancer Research Center
2007
mi
from 43215
Seattle, WA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Updated: 1/1/1970
Fred Hutchinson Cancer Research Center
2007
mi
from 43215
Seattle, WA
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Medical College of Wisconsin
330
mi
from 43215
Milwaukee, WI
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
Status: Archived
Updated: 1/1/1970
Medical College of Wisconsin
330
mi
from 43215
Milwaukee, WI
Study of ENMD-2076 in Patients With Multiple Myeloma
A Phase 1 Study of ENMD-2076 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Archived
Indiana University Adult Psychiatry Clinic
166
mi
from 43215
Indianapolis, IN
Study of ENMD-2076 in Patients With Multiple Myeloma
A Phase 1 Study of ENMD-2076 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Indiana University Adult Psychiatry Clinic
166
mi
from 43215
Indianapolis, IN
Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome
Phase II Study of Combination of Thymoglobulin, Cyclosporine, Methylprednisone, and GCSF in Patients With Newly Diagnosed Aplastic Anemia or With Hypoplastic or Low/Intermediate-1 Risk Myelodysplastic Syndrome
Status: Archived
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome
Phase II Study of Combination of Thymoglobulin, Cyclosporine, Methylprednisone, and GCSF in Patients With Newly Diagnosed Aplastic Anemia or With Hypoplastic or Low/Intermediate-1 Risk Myelodysplastic Syndrome
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
Status: Archived
University of Michigan Health Systems
164
mi
from 43215
Ann Arbor, MI
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
Status: Archived
Updated: 1/1/1970
University of Michigan Health Systems
164
mi
from 43215
Ann Arbor, MI
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Trial of Allogeneic BMT for Hematologic Malignancies Using HLA-matched Related or Unrelated Donors With Fludarabine and IV Busulfan as Pre-transplant Conditioning Followed by Post-transplant Immunosuppression With High-dose Cyclophosphamide
Status: Archived
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
345
mi
from 43215
Baltimore, MD
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Trial of Allogeneic BMT for Hematologic Malignancies Using HLA-matched Related or Unrelated Donors With Fludarabine and IV Busulfan as Pre-transplant Conditioning Followed by Post-transplant Immunosuppression With High-dose Cyclophosphamide
Status: Archived
Updated: 1/1/1970
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
345
mi
from 43215
Baltimore, MD
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Trial of Allogeneic BMT for Hematologic Malignancies Using HLA-matched Related or Unrelated Donors With Fludarabine and IV Busulfan as Pre-transplant Conditioning Followed by Post-transplant Immunosuppression With High-dose Cyclophosphamide
Status: Archived
Marcos deLima, MD
995
mi
from 43215
Houston, TX
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Trial of Allogeneic BMT for Hematologic Malignancies Using HLA-matched Related or Unrelated Donors With Fludarabine and IV Busulfan as Pre-transplant Conditioning Followed by Post-transplant Immunosuppression With High-dose Cyclophosphamide
Status: Archived
Updated: 1/1/1970
Marcos deLima, MD
995
mi
from 43215
Houston, TX
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Trial of Allogeneic BMT for Hematologic Malignancies Using HLA-matched Related or Unrelated Donors With Fludarabine and IV Busulfan as Pre-transplant Conditioning Followed by Post-transplant Immunosuppression With High-dose Cyclophosphamide
Status: Archived
Paul V. O'Donnell, M.D., Ph.D.
2007
mi
from 43215
Seattle, WA
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Trial of Allogeneic BMT for Hematologic Malignancies Using HLA-matched Related or Unrelated Donors With Fludarabine and IV Busulfan as Pre-transplant Conditioning Followed by Post-transplant Immunosuppression With High-dose Cyclophosphamide
Status: Archived
Updated: 1/1/1970
Paul V. O'Donnell, M.D., Ph.D.
2007
mi
from 43215
Seattle, WA
Collection and Banking of Leukemia Cells for Vaccine Generation in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Collection and Banking of Leukemia Cells for Vaccine Generation and Research in Patients With Advanced MDS or AML
Status: Archived
Dana-Farber Cancer Institute
643
mi
from 43215
Boston, MA
Collection and Banking of Leukemia Cells for Vaccine Generation in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Collection and Banking of Leukemia Cells for Vaccine Generation and Research in Patients With Advanced MDS or AML
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
643
mi
from 43215
Boston, MA
Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase II Study Evaluating Mechanisms of Resistance Following Treatment With Clofarabine and Daunorubicin in Newly Diagnosed Adult Acute Myeloid Leukemia Patients > or = to 60 Years Old
Status: Archived
Roswell Park Cancer Center Institute
288
mi
from 43215
Buffalo, NY
Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase II Study Evaluating Mechanisms of Resistance Following Treatment With Clofarabine and Daunorubicin in Newly Diagnosed Adult Acute Myeloid Leukemia Patients > or = to 60 Years Old
Status: Archived
Updated: 1/1/1970
Roswell Park Cancer Center Institute
288
mi
from 43215
Buffalo, NY
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
G-CSF and Plerixafor With Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation for Myeloid Leukemias
Status: Archived
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
G-CSF and Plerixafor With Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation for Myeloid Leukemias
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
A Phase 1 Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
Status: Archived
Translational Genomics Institute
1662
mi
from 43215
Phoenix, AZ
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
A Phase 1 Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
Status: Archived
Updated: 1/1/1970
Translational Genomics Institute
1662
mi
from 43215
Phoenix, AZ
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
A Phase 1 Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
Status: Archived
Premier Oncology Group
1649
mi
from 43215
Scottsdale, AZ
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
A Phase 1 Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
Status: Archived
Updated: 1/1/1970
Premier Oncology Group
1649
mi
from 43215
Scottsdale, AZ
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
A Phase 1 Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
Status: Archived
Clinical Trial Facility
643
mi
from 43215
Boston, MA
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
A Phase 1 Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
643
mi
from 43215
Boston, MA
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
A Phase 1 Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
Status: Archived
Nevada Cancer Institute
1767
mi
from 43215
Las Vegas, NV
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
A Phase 1 Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
Status: Archived
Updated: 1/1/1970
Nevada Cancer Institute
1767
mi
from 43215
Las Vegas, NV
Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias
A Multicenter Phase 1 Clinical and Pharmacokinetic Study of DCC-2036 in Subjects With Philadelphia Positive Chromosome Leukemias
Status: Archived
Tufts Clinical Pharmacology Study Unit
643
mi
from 43215
Boston, MA
Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias
A Multicenter Phase 1 Clinical and Pharmacokinetic Study of DCC-2036 in Subjects With Philadelphia Positive Chromosome Leukemias
Status: Archived
Updated: 1/1/1970
Tufts Clinical Pharmacology Study Unit
643
mi
from 43215
Boston, MA
Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias
A Multicenter Phase 1 Clinical and Pharmacokinetic Study of DCC-2036 in Subjects With Philadelphia Positive Chromosome Leukemias
Status: Archived
University of Michigan Comprehensive Cancer Center
164
mi
from 43215
Ann Arbor, MI
Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias
A Multicenter Phase 1 Clinical and Pharmacokinetic Study of DCC-2036 in Subjects With Philadelphia Positive Chromosome Leukemias
Status: Archived
Updated: 1/1/1970
University of Michigan Comprehensive Cancer Center
164
mi
from 43215
Ann Arbor, MI
Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias
A Multicenter Phase 1 Clinical and Pharmacokinetic Study of DCC-2036 in Subjects With Philadelphia Positive Chromosome Leukemias
Status: Archived
M. D. Anderson Cancer Center
795
mi
from 43215
Orlando, FL
Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias
A Multicenter Phase 1 Clinical and Pharmacokinetic Study of DCC-2036 in Subjects With Philadelphia Positive Chromosome Leukemias
Status: Archived
Updated: 1/1/1970
M. D. Anderson Cancer Center
795
mi
from 43215
Orlando, FL
High-dose HMG-CoA Inhibitor Simvastatin Relapsed CLL
High-dose HMG-CoA Inhibitor Simvastatin for Patients With Relapsed CLL: Pilot Trial and Pharmacokinetic-pharmacodynamic Studies
Status: Archived
University of Kentucky Hospital
155
mi
from 43215
Lexington, KY
High-dose HMG-CoA Inhibitor Simvastatin Relapsed CLL
High-dose HMG-CoA Inhibitor Simvastatin for Patients With Relapsed CLL: Pilot Trial and Pharmacokinetic-pharmacodynamic Studies
Status: Archived
Updated: 1/1/1970
University of Kentucky Hospital
155
mi
from 43215
Lexington, KY
A Phase 1 Study of MLN9708 in Adult Patients With Advanced Nonhematologic Malignancies
An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
Status: Archived
H. Lee Moffitt Cancer Center & Research Institute
823
mi
from 43215
Tampa, FL
A Phase 1 Study of MLN9708 in Adult Patients With Advanced Nonhematologic Malignancies
An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
Status: Archived
Updated: 1/1/1970
H. Lee Moffitt Cancer Center & Research Institute
823
mi
from 43215
Tampa, FL
A Phase 1 Study of MLN9708 in Adult Patients With Advanced Nonhematologic Malignancies
An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
Status: Archived
Sarah Cannon Cancer Center
333
mi
from 43215
Nashville, TN
A Phase 1 Study of MLN9708 in Adult Patients With Advanced Nonhematologic Malignancies
An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
Status: Archived
Updated: 1/1/1970
Sarah Cannon Cancer Center
333
mi
from 43215
Nashville, TN
Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma
Phase II Study of Revlimid (Lenalidomine), Melphalan, and Dexamethasone (ReMeDex) for Newly Diagnosed Multiple Myeloma Patients Not Undergoing Autologous Transplantation
Status: Archived
New York University Langone Medical Center
479
mi
from 43215
New York, NY
Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma
Phase II Study of Revlimid (Lenalidomine), Melphalan, and Dexamethasone (ReMeDex) for Newly Diagnosed Multiple Myeloma Patients Not Undergoing Autologous Transplantation
Status: Archived
Updated: 1/1/1970
New York University Langone Medical Center
479
mi
from 43215
New York, NY
Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma
Phase II Study of Revlimid (Lenalidomine), Melphalan, and Dexamethasone (ReMeDex) for Newly Diagnosed Multiple Myeloma Patients Not Undergoing Autologous Transplantation
Status: Archived
Bellevue Hospital Center
479
mi
from 43215
New York, NY
Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma
Phase II Study of Revlimid (Lenalidomine), Melphalan, and Dexamethasone (ReMeDex) for Newly Diagnosed Multiple Myeloma Patients Not Undergoing Autologous Transplantation
Status: Archived
Updated: 1/1/1970
Bellevue Hospital Center
479
mi
from 43215
New York, NY
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
Status: Archived
City of Hope Medical Canter
1955
mi
from 43215
Duarte, CA
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
Status: Archived
Updated: 1/1/1970
City of Hope Medical Canter
1955
mi
from 43215
Duarte, CA
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
Status: Archived
H. Lee Moffitt Cancer Center & Research Institute
823
mi
from 43215
Tampa, FL
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
Status: Archived
Updated: 1/1/1970
H. Lee Moffitt Cancer Center & Research Institute
823
mi
from 43215
Tampa, FL
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
Status: Archived
Blood and Marrow Transplant Group of Georgia
427
mi
from 43215
Atlanta, GA
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Blood and Marrow Transplant Group of Georgia
427
mi
from 43215
Atlanta, GA
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
Status: Archived
Dana-Farber Cancer Institute
643
mi
from 43215
Boston, MA
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
643
mi
from 43215
Boston, MA
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
Status: Archived
University of Minnesota Medical Center
624
mi
from 43215
Minneapolis, MN
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
Status: Archived
Updated: 1/1/1970
University of Minnesota Medical Center
624
mi
from 43215
Minneapolis, MN
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
Status: Archived
Hackensack University
476
mi
from 43215
Hackensack, NJ
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Hackensack University
476
mi
from 43215
Hackensack, NJ
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
Status: Archived
Mount Sinai Hospital
480
mi
from 43215
New York, NY
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Mount Sinai Hospital
480
mi
from 43215
New York, NY
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
Status: Archived
Ohio State University
2
mi
from 43215
Columbus, OH
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Ohio State University
2
mi
from 43215
Columbus, OH
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
Status: Archived
Hospital of the University of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Hospital of the University of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
Status: Archived
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
Status: Archived
Fred Hutchinson Cancer Research Center
2007
mi
from 43215
Seattle, WA
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Fred Hutchinson Cancer Research Center
2007
mi
from 43215
Seattle, WA
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
Status: Archived
Medical College of Wisconsin
330
mi
from 43215
Milwaukee, WI
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Medical College of Wisconsin
330
mi
from 43215
Milwaukee, WI
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
Status: Archived
TGen Clinical Research Service
1649
mi
from 43215
Scottsdale, AZ
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
Status: Archived
Updated: 1/1/1970
TGen Clinical Research Service
1649
mi
from 43215
Scottsdale, AZ
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
Status: Archived
Stanford university Hospital and Clinics
2100
mi
from 43215
Stanford, CA
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
Status: Archived
Updated: 1/1/1970
Stanford university Hospital and Clinics
2100
mi
from 43215
Stanford, CA
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
Status: Archived
University of Chicago
270
mi
from 43215
Chicago, IL
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
Status: Archived
Updated: 1/1/1970
University of Chicago
270
mi
from 43215
Chicago, IL
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
Status: Archived
National Cancer Institute (NCI)
322
mi
from 43215
Bethesda, MD
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
322
mi
from 43215
Bethesda, MD
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
Status: Archived
New York Prebyterian Hospital Cornell Medical Center
477
mi
from 43215
New York, NY
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
Status: Archived
Updated: 1/1/1970
New York Prebyterian Hospital Cornell Medical Center
477
mi
from 43215
New York, NY